VERISILICON
VeriSilicon (688521.SH) today announced the integration of its Image Signal Processor (ISP) IP ISP8000, DeWarp Processor IP DW200, and 2.5D Graphics Processor Unit (GPU) IP GCNanoV into Canaan’s K230 chip, the world’s first commercial mass production edge AIoT chip supporting the RISC-V Vector 1.0 standard. This collaboration marks a significant advancement in the high-precision, low-latency edge AIoT solutions for a wide range of intelligent products, such as large-model and multimodal input edge terminals, 3D-structured light perception modules, interactive robots, open-source hardwares, as well as hardwares for smart manufacturing, smart home solutions and AI education.
VeriSilicon’s ISP8000 IP is capable of real-time processing of three or more streams of high-definition video. Its 20-bit depth pipeline architecture supports advanced image processing algorithms such as triple-exposure High Dynamic Range (HDR) and 3D Noise Reduction (3DNR). ISP8000’s optimized software collaborates seamlessly with the RISC-V processors to efficiently manage and schedule system resources. On the K230 chip, leveraging the RT-Thread real-time operating system and the performance and power advantages of the RISC-V processors, ISP8000 can perform real-time scheduling and efficiently run software under a dual-core processor architecture. It is perfectly compatible with the K230 Software Development Kit (SDK), supporting RTOS and Linux dual operating systems, achieving an optimal balance between real-time and non-real-time operations.
VeriSilicon’s DW200 IP not only precisely corrects distortions in wide-angle or fisheye lens, but also supports multi-channel downscaling output through low-bandwidth direct link mode, enriching user application scenarios, and is particularly suited for AI applications with diverse spatial output requirements. For MCU/MPU devices, VeriSilicon’s low-power 2.5D GPU IP delivers high-performance and high-quality vector graphics processing capabilities along with superior image output.
Hong-Gang Wang, VP of research and development at Canaan said, “Leveraging VeriSilicon’s advanced pixel processing IP portfolio, our RISC-V based K230 achieved leading performance and image quality compared with other edge AIoT SoCs in its class. This enables more edge device vendors to develop innovative products with broader market applications. VeriSilicon’s ISP is one of the key factors driving innovation in our edge AIoT SoCs.”
“RISC-V is increasingly important in embedded products. We have partnered with all leading RISC-V CPU IP vendors to ensure our comprehensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio collaborates seamlessly and efficiently with RISC-V architectures,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “Through our close collaboration with Canaan, the edge AIoT SoC K230 has achieved high image quality while maintaining low power consumption and latency. Moreover, K230 can support multiple sensors leveraging the advanced Multi-Context Management (MCM) feature of ISP8000, further enhancing its market competitiveness.”
About Canaan Inc.
Canaan Inc. (Nasdaq: CAN) is a leading provider of high-performance ASIC chips. With a diversified strategy centered on “blockchain + AI”, Canaan is dedicated to the research and development of high-performance ASIC computing chips, AI chips, and devices. As a Nasdaq-listed company, Canaan holds the distinction of being the world’s “first blockchain stock company” and the initial Chinese firm with independent intellectual property in AI chips to be listed in the US. Canaan is committed to harnessing ASIC technology to achieve its mission of “Super Computing Is What We Do, Social Enrichment is Why We Do”, positioning itself as a leader in high-performance computing for blockchain and AI.
For more information, please visit: canaan.io
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313405660/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom